

DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. Profil kesehatan Indonesia tahun 2014. Jakarta : Kemenkes RI; 2015.
2. Kementrian Kesehatan Republik Indonesia. Buletin jendela data & informasi kesehatan : situasi penyakit kanker, Semester 1, 2015. Jakarta : Pusat Data dan Informasi; 2015.
3. Turgoen L.M. Clinical hematology theory and procedures 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2012. p. 307-41.
4. American Cancer Society (2017). Cancer facts & figures 2017. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/estimated-number-of-new-cancer-cases-and-deaths-by-sex-us-2017.pdf> - Diakses September 2017.
5. American cancer society. Cancer facts & figures 2017. Atlanta: American Cancer Society Inc.; 2017: 16.
6. Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, *et al.* Chronic myeloid leukemia in Asia. *Int J hematol*; 2009: 89: 14-23.
7. Fadjari H, Sukrisman L. Leukemia granulositik kronik. Dalam : Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku ajar ilmu penyakit dalam edisi VI, Jilid II. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2014. p. 2678-82.
8. Hoffbrand AV, Moss PAH. Kapita selekta hematologi edisi 6. Jakarta: Penerbit Buku Kedokteran EGC; 2014.p. 178-185
9. Reksodiputro AH, Tadjoein H, Rinaldi I, Witarto AB. Clinical characteristic, hematologic response and gene mutation of patients with chronic phase chronic myeloid leukemia to imatinib at Cipto Mangunkusumo National Hospital. *Indonesian Journal of Cancer*;2011: 5(4): 147-151.

10. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. *Blood Journal*; 1999; 94(5): 1517-36.
11. Kartawan GA, Suega K, Rena RA. Karakteristik klinis pasien *chronic myeloid leukemia* dengan terapi *tyrosine kinase inhibitor* di Rumah Sakit Umum Pusat Sanglah. *E-Jurnal Medika Udayana*; 2015: 4(9).
12. Siegel, R, Naishadham, P, Jemal, A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; 63(1): 11-30.
13. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK 02.02/MENKES/137/2015 Tentang Formularium Nasional. Jakarta: Menteri Kesehatan Republik Indonesia; 2016.
14. Putra IMBA, Rena RA, Suega K. Respon hematologi pasien leukemia mieloid kronik yang mendapat pengobatan tyrosine kinase inhibitor selama setahun di RSUP Sanglah Denpasar. *E-Jurnal Medika Udayana*; 2015: 4(12).
15. Kennedy BJ, Yarbrow JW. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. *JAMA* 1966; 195(12):162-167.
16. Ganiswarna S, Nafrialdi. Antikanker. Dalam : Gunawan SG, Setiabudy S, Nafrialdi, Elysabeth, editors. *Farmakologi dan terapi* edisi V. Jakarta : Balai Penerbit FK UI; 2012. p. 753-54.
17. Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, editors. *Wintrobe's clinical hematology* 11th edition. Philadelphia : Lippincott-Williams & Wilkins; 2004.
18. Price SA, Wilson LM. *Patofisiologi: konsep klinis proses - proses penyakit* edisi 6 volume 1. Jakarta : EGC; 2015. p. 271-281.
19. Kurnianda J. Leukemia mieloblastik akut. Dalam : Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. *Buku ajar ilmu penyakit dalam* edisi VI, jilid II. Jakarta : Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2014. p. 2671-77

20. Riadi W. Pemeriksaan morfologi dan sitokimia pada leukemia akut. *Majalah Kedokteran Indonesia*; 2002: 52(6) : 217-223.
21. Calistania C, Mulansari NA. Leukemia granulositik kronik. Dalam : Tanto C, Liwang F, Hanifati S, Pradipta EA, editors. *Kapita selekta kedokteran edisi IV*. Jakarta : Media Aesculapius; 2014. p.662-3
22. Bakta IM. *Hematologi klinik ringkas*. Jakarta :Penerbit Buku Kedokteran EGC; 2014. p. 122, 137-144.
23. Launder TM, Lawnicki LC, Perkins ML. Introduction to leukemia and the acute leukemias. In: Harmening DM, eds. *Clinical hematology and fundamental of hemostasis edition 4*. Philadelphia: FA. Davis Company; 2002: 272-357.
24. Simamora I. *Karakteristik penderita leukemia rawat inap di RSUP H.Adam Malik Medan tahun 2004-2007*. Medan : Universitas Sumatera Utara Repository; 2009.
25. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). *Best Practice & Research Clinical Haematology*; 2009: 22(3): 295-302.
26. Universitas Sumatera Utara. <http://repository.usu.ac.id/bitstream/handle/123456789/46852/Chapter%20II.pdf?sequence=3&isAllowed=y> – Diakses Agustus 2017.
27. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. *The Lancet*. Elsevier; 2007: 370(9584): 342-50.
28. Esfahani MK, Morris EL, Dutcher JP, Wiernik PH. Blastic phase of chronic myelogenous leukemia. *Current Treatment Options in Oncology*. USA; 2006: 7(3): 189-199.
29. Hehlmann R. How I treat CML blast crisis. *Blood journal*; 2012: 120(4): 737-747.
30. Mehta, Atul, Hoffbrand V. *At a glance hematologi edisi kedua*. Jakarta : Erlangga; 2005.

31. Besa, EC. Chronic myelogenous leukemia. <https://emedicine.medscape.com/article/199425-overview> - Diakses September 2017.
32. Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia for children : a review. Environmental health perspective. Atlanta; 2007: 115(1): 138-145
33. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006. p.63.
34. Polovich M., White JM, Kelleher LO. Chemotherapy and biotherapy guidelines and recommendations for practice 2nd edition. Pittsburgh : Oncology Nursing Society; 2005.
35. Bubnoff NV, Duyster J. Chronic myelogenous leukemia treatment and monitoring. Deutsches Ärzteblatt International; 2010: 107(7): 114–21.
36. Bristol-Myers Squibb Canada. HYDREA[®] product monograph. http://www.bmscanada.ca/static/products/en/pm_pdf/HYDREA_EN_PM.pdf-Diakses September 2017.
37. BC Cancer Agency Cancer Drug Manual. Hydroxyurea. <http://www.bccancer.bc.ca/drug-database-site/Drug%20Index?Hydroxyurea> monograph 1Oct2013.pdf – Diakses September 2017.
38. McEvoy GK. AHFS 2006 drug information. Maryland : American Society of Health System Pharmacists Inc.; 2006. p.1067 – 1072.
39. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology : chronic myelogenous leukemia. Washington. NCCN Inc.; 2017.
40. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med; 2003: 34: 994–1004.

41. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med*; 2003; 349: 1423–32.
42. Bolin RW, Robinson WA, Sutherland J, Hamman RF. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. *American Cancer Society Inc.*;1982: 50(9):1683-6.
43. Dahlan, MS. Langkah-langkah membuat proposal penelitian bidang kedokteran dan kesehatan edisi 2. Jakarta : Sagung Seto; 2016.p.89-90.
44. Sastroasmoro S, Ismael S. Dasar-dasar metodologi penelitian klinis edisi ke-5. Jakarta : Sagung Seto; 2014.p.362-3.
45. Rendra M, Yaswir R, Hanif AM. Gambaran laboratorium leukemia kronik di bagian penyakit dalam RSUP Dr. M. Djamil Padang. Padang : *Jurnal Kesehatan Andalas*; 2013: 2(3) : 141-145.
46. Bruner & Suddarth's. 2002. *Buku Ajar Keperawatan Medikal Bedah*. Jakarta: EGC.
47. NIH National Cancer Institute. Chronic Myelogenous Leukemia Treatment. [https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq#section/ 31](https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq#section/31)– Diakses pada desember 2017.
48. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MI, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. *Blood Journal*; 2002: 100(2): 435-41.
49. American Cancer Society. How Do You Know If Treatment for Chronic Myeloid Leukemia Is Working. <https://www.cancer.org/cancer/chronic-myeloid-leukemia/treating/is-treatment-working.html> - Diakses pada januari 2018.
50. Cheng Y, Walkom E. Proposal for the inclusion of hydroxyurea in the who model list of essential medicines. makalah disajikan dalam 17th Expert Committee On The Selection And Use Of Essential Medicines, Geneva, 2009.

51. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. *Jurnal of Clinical Oncology*; 2009.
52. Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. *Cancer*; 1972: 29(4):1052-6.
53. Kennedy BJ, Yarbrow JW. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. *JAMA*; 1966: 195:1038-43.
54. Fishbein WN, Carbone PP, Freireich EJ, Misra D, Frei E. Clinical trials of hydroxyurea in patients with cancer and leukemia. *Clin.Pharmacology Therapy*;1964: 5:574-80.
55. Tanzer J, Jacquillat C, Weil M, Levy D, Najean Y, Boiron M, Bernard J. Hydroxyurea in the treatment of chronic myeloid leukemia. *Presse Med.*;1966: 74:2929-30.
56. George S, Horvath L, Molokie R, Berry J, Rondelli D, Hoffman R. Response to Therapy with Imatinib Mesylate in Patients with CML Is Poor in Non-Caucasian Patients. *Blood Journal*; 2004: 104:2937.
57. Ibrahim C. Haznedaroglu. Monitoring the response to tyrosine kinase inhibitor (tki) treatment in chronic myeloid leukemia (cml). *Mediterranean journal of hematology and infection disease*; 2014.
58. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK. Randomized Comparison of Interferon- α With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia. *Blood Journal*; 1994: 84(12): 4064-77.
59. National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology : Chronic Myelogenous Leukemia. Washington. NCCN Inc.; 2015.
60. Razavi M. Hematologic and Molecular Responses to Generic Imatinib in Patients With Chronic Myeloid Leukemia. *The journal for laboratory professionals*; 2010.
61. Michael R. Savona, Saglio G. Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia. *Acta Hematologica*; 2013.